← The Wire
ALLONasdaq
Allogene Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · CIK 1737287
Developing allogeneic T cell product candidates for cancer and autoimmune diseases
red 8-K · 90d
$656M
Market cap
$2.22
Last close
+4.2%
1D
+5.7%
5D
14.7M
Volume
Price · last 39 sessions-1.8%
May 4L $1.78 · H $2.33Jun 29
158
Total filings
Jun 22, 2026
Last filing
12/31
Fiscal year end
8-KShareholder Vote · Company UpdateJun 22, 2026424B5424B5Jun 22, 2026DEFA14ADEFA14AMay 28, 20268-KExecutive ChangeMay 28, 2026DEFA14ADEFA14AMay 21, 202610-Q10-QMay 13, 20268-KMaterial Agreement · Agreement TerminatedMay 13, 2026DEFA14ADEFA14AApr 30, 2026DEF 14ADEF 14AApr 30, 20268-KCompany UpdateApr 15, 2026424B5424B5Apr 15, 2026424B5424B5Apr 13, 20268-KCompany UpdateApr 13, 20268-KCompany UpdateApr 13, 202610-K10-KMar 12, 20268-KResults of OperationsMar 12, 2026SC 13D/ASC 13D/AFeb 13, 202610-Q10-QNov 6, 20258-KResults of OperationsNov 6, 20258-KCompany UpdateOct 14, 202510-Q10-QAug 13, 20258-KResults of OperationsAug 13, 20258-KCompany UpdateAug 1, 20258-KShareholder VoteJun 23, 202510-Q10-QMay 13, 20258-KResults of OperationsMay 13, 2025DEFA14ADEFA14AApr 30, 2025DEF 14ADEF 14AApr 30, 202510-K10-KMar 13, 20258-KResults of OperationsMar 13, 20258-KMaterial AgreementFeb 25, 20258-KExecutive ChangeJan 29, 20258-KCompany UpdateNov 13, 202410-Q10-QNov 7, 20248-KResults of OperationsNov 7, 2024SC 13GSC 13GNov 4, 20248-KCode of EthicsOct 7, 202410-Q10-QAug 7, 20248-KResults of OperationsAug 7, 20248-KExecutive Change · Shareholder VoteJun 10, 20248-KMaterial AgreementMay 31, 20248-KCompany UpdateMay 14, 2024424B5424B5May 14, 202410-Q10-QMay 13, 20248-KResults of OperationsMay 13, 2024DEFA14ADEFA14AApr 23, 2024DEF 14ADEF 14AApr 23, 202410-K10-KMar 14, 20248-KResults of OperationsMar 14, 202410-K/A10-K/AMar 14, 20248-KRestatementFeb 16, 20248-KMaterial AgreementJan 31, 20248-KMaterial Agreement · Exit / Disposal CostsJan 5, 20248-KCompany UpdateDec 19, 2023424B5424B5Nov 2, 202310-Q10-QNov 2, 20238-KResults of OperationsNov 2, 20238-K/AExecutive ChangeOct 17, 20238-KExecutive ChangeOct 16, 202310-Q10-QAug 2, 20238-KResults of OperationsAug 2, 2023SC 13GSC 13GJul 10, 20238-KCompany UpdateJun 21, 20238-KShareholder VoteJun 15, 20238-KExecutive ChangeJun 14, 20238-KCompany UpdateJun 7, 202310-Q10-QMay 3, 20238-KResults of OperationsMay 3, 2023DEFA14ADEFA14AApr 24, 2023DEF 14ADEF 14AApr 24, 20238-KExecutive ChangeApr 20, 20238-KReg FD DisclosureMar 10, 202310-K10-KFeb 28, 20238-KResults of OperationsFeb 28, 2023SC 13GSC 13GFeb 13, 2023SC 13GSCHEDULE 13GFeb 9, 2023SC 13GSC 13GFeb 3, 2023SC 13GSC 13GFeb 3, 20238-KExecutive ChangeJan 3, 20238-KCompany UpdateNov 29, 2022
Insider Activity
In the 90 days to Mar 16, 2026: 6 sold $527K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 16, 2026 | Chang David DPresident and CEO | Sell | 47,763 | $2.47 | $118K |
| Mar 16, 2026 | Beneski Benjamin MachinasSVP, Chief Technical Officer | Sell | 4,835 | $2.47 | $12K |
| Mar 2, 2026 | Beneski Benjamin MachinasSVP, Chief Technical Officer | Sell | 7,132 | $2.60 | $19K |
| Feb 2, 2026 | Chang David DPresident and CEO | Sell | 95,269 | $1.80 | $171K |
| Feb 2, 2026 | Roberts ZacharyEVP of R&D | Sell | 35,700 | $1.77 | $63K |
| Feb 2, 2026 | Parker Geoffrey M.CHIEF FINANCIAL OFFICER | Sell | 24,001 | $1.76 | $42K |
| Feb 2, 2026 | Douglas Earl MartinSVP, General Counsel | Sell | 22,900 | $1.76 | $40K |
| Feb 2, 2026 | Beneski Benjamin MachinasSVP, Chief Technical Officer | Sell | 7,549 | $1.73 | $13K |
| Feb 2, 2026 | Yoshiyama AnnieSVP, Finance | Sell | 4,167 | $1.72 | $7K |
| Jan 21, 2026 | Roberts ZacharyEVP of R&D | Sell | 26,269 | $1.56 | $41K |
| Nov 17, 2025 | Beneski Benjamin MachinasSVP, Chief Technical Officer | Sell | 786 | $1.22 | $959 |
| Oct 21, 2025 | Parker Geoffrey M.CHIEF FINANCIAL OFFICER | Sell | 36,744 | $1.26 | $46K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance